Court Upholds Pfizer Patent For Norvasc

Law360, New York (January 18, 2006, 12:00 AM EST) -- Pfizer, deflecting challenges from several generic drug makers over the patents for its second best-selling drug Norvasc, has prevailed in one of the cases, with a judge blocking an attempt by Apotex to launch a generic version of the blood pressure treatment.

A judge in an Illinois District Court upheld Pfizer’s patent for the main ingredient in the drug, which is not set to expire until September 2007.

The blockbuster blood pressure drug is Pfizer’s second-biggest earner, bringing in $3.46 billion, or 9% of corporate sales,...
To view the full article, register now.